The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Safety and efficacy of daratumumab with lenalidomide and dexamethasone in relapsed or relapsed, refractory multiple myeloma.
Torben Plesner
Employment or Leadership Position - Celgene; Janssen Pharmaceutical
Consultant or Advisory Role - Genmab
Hendrik-Tobias Arkenau
No relevant relationships to disclose
Henk M. Lokhorst
Consultant or Advisory Role - Genmab
Honoraria - Celgene; Janssen-Cilag; Mundipharma
Research Funding - Genmab
Peter Gimsing
No relevant relationships to disclose
Jakub Krejcik
No relevant relationships to disclose
Charlotte Rose Lemech
No relevant relationships to disclose
Monique Minnema
Consultant or Advisory Role - Janssen-Cilag
Honoraria - Janssen-Cilag
Ulrik Niels Lassen
No relevant relationships to disclose
Tahamtan Ahmadi
Employment or Leadership Position - Janssen Research & Development
Howard Yeh
Employment or Leadership Position - Janssen Research & Development
Mary Guckert
Employment or Leadership Position - Janssen Research & Development
Nikolai C. Brun
Employment or Leadership Position - Genmab
Steen Lisby
Employment or Leadership Position - Genmab
Stock Ownership - Genmab
Linda Basse
Employment or Leadership Position - Genmab
Antonio Palumbo
Consultant or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Janssen Pharmaceutical ; Onyx
Honoraria - Amgen; Bristol-Myers Squibb; Celgene; Janssen Pharmaceutical ; Onyx
Paul G. Richardson
Consultant or Advisory Role - Bristol-Myers Squibb; Celgene; Johnson & Johnson; Millennium; Novartis